**Study includes country-level data for 204 countries and territories worldwide, see summary tables at end of release**
Despite recent advancements in breast cancer treatments, new breast cancer cases in women are predicted to rise by a third globally from 2.3 million in 2023 to more than 3.5 million in 2050. Similarly, yearly deaths from the disease are projected to surge 44%, from around 764,000 to 1.4 million, with disproportionate impact in countries with limited resources, according to a major new analysis from the Global Burden of Disease Study Breast Cancer Collaborators, published in The Lancet Oncology .
Importantly, the findings suggest that maintaining a healthy lifestyle, including not smoking, getting sufficient physical activity, lowering red meat consumption, and having a healthy weight may prevent over a quarter of healthy years lost to illness and premature death due to breast cancer worldwide.
“Breast cancer continues to take a profound toll on women’s lives and communities,” said lead author Kayleigh Bhangdia from the Institute for Health Metrics and Evaluation (IHME), University of Washington, USA. “While those in high-income countries typically benefit from screening and more timely diagnosis and comprehensive treatment strategies, the mounting burden of breast cancer is shifting to low- and lower middle-income countries where individuals often face later-stage diagnosis, more limited access to quality care, and higher death rates that are threatening to eclipse progress in women’s health.”
Using data from population-based cancer registries, vital registration systems, and interviews with family members or caregivers of women who have died from breast cancer, the new analysis provides an updated global, regional, and national analysis of the female breast cancer burden and risk factor estimates from 1990 to 2023 in 204 countries and territories, with forecasts up to 2050. Importantly, the study also estimates the number of years of healthy life that women with breast cancer have lost to illness, disability, and premature death.
Rates of new cases remain highest in HICs, but growing fastest in LICs
Breast cancer remains the most common cancer among women worldwide, with an estimated 2.3 million new breast cancers diagnosed worldwide in women in 2023 (with 73% or 1.67 million cases occurring in high- and upper-middle-income countries) and 764,000 resulting deaths (with 39% or 300,000 deaths occurring in low- and lower-middle-income countries).
When global cases and death rates are adjusted to account for differences in age (to allow comparisons between countries and over time), the study reveals striking inequalities in the burden of breast cancer. For example, in 2023, breast cancer age-standardised incidence rates were on average highest in high-income countries (HICs), including Monaco, Andorra, France, Germany and Ireland (100 new cases per 100,000 women or higher), and lower in low- and middle-income countries (LMICs), including Afghanistan, Somalia, and Mozambique (13 new cases per 100,000 women or lower) in 2023.
However, age-standardised rates of new cases have risen sharply (up 147% on average) since 1990 in low-income countries (LICs), but remained stable in HICs, highlighting the disproportionate growth occurring in settings with lower resources (see table 1 in the paper).
Moreover, between 1990 and 2023, age-standardised death rates from breast cancer in HICs fell on average 30% to 16 deaths per 100,000 women, but almost doubled in LICs to 24 deaths per 100,000 women, exposing likely disparities in timely diagnosis and access to quality treatment.
Globally, the number of years of healthy life lost due to poor health and early death more than doubled from 11.7 million years in 1990 to 24 million years in 2023. However, although women in low- and lower-middle-countries account for 27% (around 628,000) of new cases globally, they contribute to more than 45% of all the ill-health and early deaths from breast cancer globally (nearly 11 million years of healthy life lost).
“LMICs are hit hardest by escalating breast cancer burden as many of these nations grapple with lifestyle and demographic changes alongside health systems that are less equipped than ideal to respond, with shortages of radiotherapy machines, chemotherapy drugs, and pathology labs, and standard treatments that can be quite costly,” explained co-author Dr Olayinka Ilesanmi, a physician and epidemiologist from Nigeria working for the Africa CDC. “Although survival continues to improve in HICs, reflecting success in breast cancer screening, diagnosis, and treatment, even within HICs, outcomes can still depend on where a woman lives.”
Rise in pre-menopausal breast cancer
Globally, three times as many new breast cancer cases were diagnosed in women aged 55 or older in 2023 (161 vs 50 new cases per 100,000 women) compared to women aged 20-54 years. However, rates of new cases have risen in women aged 20-54 years old (up 29%) since 1990, with rates in older women not changing substantially—these differences may reflect changing age patterns as well as changes in risk factors, which vary between pre- and post-menopausal women.
Impact of uncontrolled risk factors
In 2023, 28% of the global breast cancer burden (6.8 million years of healthy life lost to disability, illness and early death) was linked to six potentially modifiable risk factors. High red meat consumption had the biggest impact (linked to nearly 11% of all healthy life lost), followed by tobacco use (including second-hand smoke; 8%), high blood sugar (6%), high body mass index (BMI; 4%), and high alcohol use and low physically activity (both 2%).
Substantial progress has been made in reducing the global breast cancer burden linked to high alcohol use and tobacco between 1990 and 2023, which declined by 47% and 28%, respectively, while the breast cancer burden linked to other risk factors did not indicate the same progress over time.
“With more than a quarter of the global breast cancer burden linked to six modifiable lifestyle changes there are tremendous opportunities to alter the trajectory of breast cancer risk for the next generation,” said co-senior author Dr Marie Ng, Affiliate Associate Professor at IHME and Associate Professor at National University of Singapore. “Targeting known risk factors through public health policies and making healthier choices more accessible, while working with individuals to take action to reduce obesity and high blood sugar, is crucial to halting the rise in breast cancers worldwide.”
Ensuring all women have an equal chance to survive breast cancer
Even with the best prevention policies, millions of women will still develop breast cancer, which makes closing the care gap an urgent priority. The authors stress that with fair access to care in low-resource settings, investment in innovative therapies, and strong political will, there is an opportunity to ensure that all women have an equal chance to overcome breast cancer.
As Dr Lisa Force, co-senior author from IHME explained, “Collaborative efforts are needed to ensure well-functioning health systems capable of early diagnosis and comprehensive treatment of breast cancer in all countries. Reducing the cost of breast cancer therapies and ensuring that universal health coverage includes breast cancer care essentials would also be valuable in protecting patients from catastrophic costs and improving outcomes.”
While the study uses the best available data, the authors note that the estimates are constrained by a lack of high-quality cancer registry data, particularly in countries with limited resources, highlighting the need to increase investments in cancer surveillance systems. They also note that information on cancer stage at diagnosis and subtype are not included in the analysis despite their distinct survival patterns and resource implications due to data limitations, and the analysis does not analyse the impact of the COVID-19 pandemic or recent conflicts on the disease burden.
Writing in a linked Comment, Professor Yeon Hee Park from Sungkyunkwan University School of Medicine, Seoul, South Korea (who was not involved with the study) noted that, “Without ethnic or genetic ancestry data, the study cannot distinguish whether observed regional differences reflect genetic predisposition, environmental exposures, health-care disparities, or combinations thereof…Despite these limitations, this study provides a necessary foundation for global health planning…With appropriate refinements, particularly ethnic and genetic ancestry stratification that acknowledges the distinctive molecular signatures of African, Asian, and other ethnic and genetic ancestry populations, this study can achieve its goal of informing evidence-based cancer control strategies worldwide.”
Summary tables of findings:
Table 1
Global breast cancer rates:
Cases (thousands)
(95% UI)
Deaths (thousands)
(95% UI)
ASIR (per 100,000)
(95% UI)
ASMR (per 100,000)
(95% UI)
1990
924
(836 to 1030)
363
(337 to 391)
42.4
(38.3 to 47.2)
17.0
(15.8 to 18.3)
2023
2300
(2010 to 2610)
764
(672 to 854)
49.3
(43.3 to 56.1)
16.1
(14.2 to 18.1)
2050
3560
(2290 to 4830)
1370
(841 to 2020)
49.1
(35.1 to 63.9)
16.7
(11.3 to 24.0)
Table 2
Country breast cancer rates (for more country-level data, see https://cloud.ihme.washington.edu/s/iDnqW7jaPz7ENcB ):
Country
ASIR (per 100,000) in 1990
(95% UI)
ASIR (per 100,000) in 2023
(95% UI)
ASIR percentage change, 1990 to 2023
(95% UI)
ASMR (per 100,000) in 1990
(95% UI)
ASMR (per 100,000) in 2023
(95% UI)
ASMR percentage change, 1990 to 2023
(95% UI)
Largest + change ASIR (Equatorial Guinea)
23.6
(15.5 to 34.7)
107.0
(67.9 to 151.1)
354.2
(137.8 to 678.1)
16.4
(10.7 to 23.8)
51.3
(32.2 to 72.0)
212.0
(67.0 to 416.2)
Largest + change ASMR (Lao People’s Democratic Republic)
13.1
(8.5 to 20.4)
53.9
(35.7 to 77.1)
311.9
(114.7 to 607.9)
9.4
(6.1 to 14.7)
29.6
(19.8 to 41.9)
214.4
(64.8 to 446.2)
Largest - change ASIR and ASMR (Denmark)
123.9
(113.8 to 133.8)
84.6
(73.2 to 96.9)
-31.7
(-42.9 to - 20.4)
51.7
(48.5 to 54.2)
22.2
(19.7 to 24.3)
-57.2
(-61.2 to - 53.0)
Australia
78.9
(73.6 to 85.0)
74.5
(65.6 to 84.4)
-5.6
(-17.4 to 7.9)
26.5
(25.0 to 28.0)
14.4
(12.5 to 16.1)
-45.8
(-50.9 to -40.1)
China
24.5
(19.7 to 30.8)
31.6
(25.4 to 38.2)
28.8
(-4.0 to 72.6)
10.6
(8.8 to 13.5)
6.8
(5.7 to 8.0)
-36.6
(-53.2 to
-16.8)
France
80.5
(71.4 to 89.8)
114.6
(98.4 to 134.0)
42.5
(16.3 to 73.3)
27.0
(25.6 to 28.2)
20.6
(18.0 to 23.6)
-23.7
(-32.9 to
-13.3)
Germany
82.4
(74.1 to 91.8)
100.4
(89.8 to 111.5)
21.8
(5.3 to 40.5)
28.8
(27.2 to 30.2)
22.2
(19.9 to 24.3)
-23.1
(-30.2 to -16.7)
India
13.0
(9.4 to 16.3)
29.4
(22.8 to 37.1)
126.9
(67.6 to 219.9)
8.9
(6.4 to 11.3)
15.5
(11.8 to 19.5)
74.0
(30.7 to 138.6)
Spain
68.7
(61.1 to 76.5)
65.0
(55.1 to 75.9)
-5.4
(-21.4 to 14.1)
23.9
(22.6 to 25.1)
13.9
(12.2 to 15.3)
-41.9
(-47.2 to
-36.7)
United Kingdom
102.9
(93.3 to 111.6)
89.5
(79.7 to 100.8)
-13.1
(-24.8 to 0.6)
36.5
(34.2 to 38.5)
20.8
(18.8 to 22.4)
-43.0
(-47.1 to
-38.5)
Ireland
95.5
(84.3 to 107.6)
100.0
(83.2 to 118.4)
4.8
(-14.1 to 27.9)
33.5
(31.0 to 36.0)
20.5
(17.9 to 23.2)
-38.7
(-46.9 to -29.0)
United States of America
128.6
(113.0 to 144.3)
92.5
(79.6 to 107.4)
-28.1
(-41.3 to
-13.7)
28.3
(26.1 to 30.2)
16.8
(14.8 to 18.7)
-40.8
(-46.4 to
-33.4)
UI = Uncertainty Interval
ASIR = Age-Standardised Incidence Rate
ASMR = Age-Standardised Mortality Rate
NOTES TO EDITORS
The study was funded by the Gates Foundation and St Jude Children’s Research Hospital. It was conducted by the GBD 2023 Breast Cancer Collaborators.
The labels have been added to this press release as part of a project run by the Academy of Medical Sciences seeking to improve the communication of evidence. For more information, please see: http://www.sciencemediacentre.org/wp-content/uploads/2018/01/AMS-press-release-labelling-system-GUIDANCE.pdf if you have any questions or feedback, please contact The Lancet press office pressoffice@lancet.com.
PLEASE USE THE FOLLOWING, WHICH WILL GO LIVE AT THE TIME THE EMBARGO LIFTS: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00730-2/fulltext
The Lancet Oncology
C Agostinis Sobrinho reports support for the present manuscript from Fundação para a Ciência e a Tecnologia (FCT; Portugal; CEECINST/00093/2021/CP2815/CT0001) and by FCT within the framework of the Sport, Physical Activity and Health Research & Innovation Center (UID/6185/2023). R Ancuceanu reports consulting fees from Abbvie and Merck Romania; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Abbvie, Laropharm, Reckitt, and Merck Romania; and support for attending meetings and travel from Merck Romania and Reckitt; all outside the submitted work. M S Aslam reports grants or contracts outside the submitted work from Xiamen University Malaysia Research Fund (XMUMRF; grant number MUMRF/2025-C15/ ITCM/0006; project title: therapeutic and toxicity evaluation of selected medicinal herbs for nafld: exploring the inter-organelle contact sites modulation theory; role: co-investigator; dates: January, 2025, to December, 2027 [ongoing], internal XMUMRF research grant administered by Xiamen University Malaysia; funds disbursed to institutional research account only; no salary, honoraria, or personal payments to author; and grant number XMUMRF/2023-C11/ISEM/0041; project title: children’s rights education in the early years of divorce: an exploration of adolescents’ perspectives; role: co-investigator; dates: January, 2023 to December, 2025 [ongoing]; internal XMUMRF research grant administered by Xiamen University Malaysia; funds disbursed to institutional research account only; no salary, honoraria, or personal payments to author). A K M Azad reports support for the present manuscript from Imam Mohammad Ibn Saud Islamic University (IMSIU; Riyadh 13318, Saudi Arabia) and other financial or nonfinancial interests outside the submitted work from the Deanship of Scientific Research, (IMSIU, Riyadh 13318, Saudi Arabia). E C Dee reports support for the present manuscript from the Prostate Cancer Foundation Young Investigator Award and through the Cancer Center Support Grant from the National Cancer Institute (P30 CA008748). L M Force reports support for the present manuscript from Gates Foundation and St Jude Children’s Research Hospital; grants or contracts from St. Baldrick’s Foundation, Conquer Cancer Foundation, and NIH Loan Repayment Program, outside the submitted work; leadership or fiduciary roles in board, society, committee, or advocacy groups, unpaid with the Lancet Oncology International Advisory Board, outside the submitted work. A Guha reports grants or contracts from the American Heart Association and the US Department of Defense; leadership or fiduciary roles in board, society, committee, or advocacy groups, paid or unpaid with the ZERO Prostate Cancer Health Equity Task Force; all outside the submitted work. C Herteliu reports grants or contracts from the project “Analysis of the impact of COVID-19 on the main demographic indicators in Romania and the Republic of Moldova by using econometric modeling” code PN-IV-P8-8.3-ROMD-2023-0208 funded by the Romanian Ministry of Research, Innovation and Digitalization through UEFISCDI, grant of the European Commission Horizon 4P-CAN (Personalised Cancer Primary Prevention Research through Citizen Participation and Digitally Enabled Social Innovation), the project “Societal and Economic Resilience within multi-hazards environment in Romania” funded by EU NextgenerationEU, and the Romanian Government, under the National Recovery and Resilience Plan for Romania (contract number 760050/ 23.05.2023, cod PNRR-C9-I8-CF 267/ 29.11.2022), through the Romanian Ministry of Research, Innovation, and Digitalization, within Component 9, Investment I8, and the project “A better understanding of socioeconomic systems using quantitative methods from Physics” funded by EU NextgenerationEU and the Romanian Government, under National Recovery and Resilience Plan for Romania (contract number 760034/ 23.05.2023, cod PNRR-C9-I8-CF 255/ 29.11.2022), through the Romanian Ministry of Research, Innovation, and Digitalization, within Component 9, Investment I8, all outside the submitted work. I M Ilic reports support for the present manuscript from the Ministry of Science, Technological Development, and Innovation of the Republic of Serbia (number 451-03- 137/2025-03/200110). M D Ilic reports support for the present manuscript from the Ministry of Science, Technological Development and Innovation of the Republic of Serbia (number 451-03-47/2023- 01/200111). T Joo reports support for the present manuscript from the National Research, Development and Innovation Office in Hungary (RRF-2.3.1-21-2022-00006, Data-Driven Health Division of National Laboratory for Health Security). J J Jozwiak reports payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Novartis, Adamed, Amgen, Boehringer Ingelheim, and Servier, all outside the submitted work. M K Kashyap reports grants or contracts from the Indian Council of Medical Research (ICMR), New Delhi (# 5/13/55/2020/NCD-III; patents 2023-1100-3940 [Indian Patent-Pending] and 2023-1105-8515 [Indian Patent-Pending]); all outside the submitted work. J M Kocarnik reports support for the present manuscript from the Institute for Health Metrics and Evaluation as an employee, the Gates Foundation (paid to his institution), and American Lebanese Syrian Association Charities (paid to his institution). M-C Li reports grants or contracts from the National Science and Technology Council, Taiwan (NSTC 113-2314-B-003-002) and the “Higher Education Sprout Project” of National Taiwan Normal University; leadership or fiduciary roles in board, society, committee or advocacy groups, paid or unpaid with the Journal of the American Heart Association as Technical Editor; all outside the submitted work. K S-K Ma reports a research grant from the International Team for Implantology outside the submitted work. H R Marateb reports grants or contracts from Universitat Politècnica de Catalunya (UPC) via salary, outside the submitted work. S A Meo reports grants or contracts from the Ongoing Research Funding Program (ORF-2025-47), King Saud University, Riyadh, Saudi Arabia outside the submitted work. S Nomura reports support for the present manuscript from Ministry of Education, Culture, Sports, Science and Technology of Japan (24H00663), Precursory Research for Embryonic Science and Technology from the Japan Science and Technology Agency (JPMJPR22R8), and National Cancer Center Research and Development Fund (2024-A-14), all outside the submitted work. B Oancea reports support for the present manuscript from the MRID, project PNRR-I8 number 842027778, contract number 760096. S K Panda reports support for the present manuscript from Siksha ‘O’ Anusandhan (deemed to be University) via salary; grants or contracts outside the submitted work (from file number 17-59/2023-24/CCRH/Tech./Coll./ICMR-Diabetes/960) as coinvestigator. R Passera reports participation on a Data Safety Monitoring Board or Advisory Board as Member of the Data Safety Monitoring Board dello studio “Consolidation with ADCT-402 (loncastuximab tesirine) after immunochemotherapy: a phase II study in BTKi-treated/ ineligible Relapse/Refractory Mantle Cell Lymphoma (MCL) patients” – Fondazione Italiana Linfomi, Alessandria (Italy), unpaid; leadership or fiduciary roles in board, society, committee or advocacy groups, unpaid, as Member of the EBMT Statistical Committee, European Society for Blood and Marrow Transplantation, Paris (France), and as past Member 2020-2023 (biostatistician) of the IRB/IEC Comitato Etico AO SS. Antonio e Biagio Alessandria-ASL AL-VC (Italy); all outside the submitted work. R G Pestell reports support for the present manuscript from research grants W81XWH-22-BCRP and RGH_L_2024, from CytoDyn as a consultant, via travel support, as owner of stock and warrants and sponsored research, from StromaGenesis, EcoGenome, and LightSeed as CEO and owner of company and patents, from Shenandoah Pharmaceuticals; and ioROC Therapeutics as CEO and owner of company; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events outside the submitted work from HUN_REN National Advisory Board (Hungary) and National Cancer Institute NCI Cancer Center Reviewer – subcommittee A. Y L Samodra reports grants or contracts from School of Public Health, TMU, Taiwan; leadership or fiduciary roles in board, society, committee or advocacy groups, paid or unpaid with Benang Merah Research Center (benangmerah.net) as Co-Founder; other financial or non-financial interest with Jago Beasiswa (idebeasiswa.com) as Scholarship Mentor; all outside the submitted work. M Šekerija reports consulting fees from Roche; payment of honoraria for lectures, presentations, speakers, bureaus, manuscript writing or educational events from Astellas; all outside the submitted work. V Sharma reports other financial or non-financial support from DFSS (MHA)’s research project (DFSS28(1)2019/EMR/6) at Institute of Forensic Science & Criminology, Panjab University, Chandigarh, India, and RUSA grant to Panjab University by Ministry of Education, Government of India, outside the submitted work. V Shivarov reports a patent with the Bulgarian Patent Office; other financial or non-financial interests from ICON plc via a salary; all outside the submitted work. M Sikdar reports other financial or non-financial interests outside the submitted work with the Anthropological Survey of India; all opinions expressed by the author are entirely personal and do not reflect the views or official position of the Anthropological Survey of India. J A Singh reports consulting fees from ROMTech, Atheneum, Clearview Healthcare Partners, Yale, Hulio, Horizon Pharmaceuticals/DINORA, ANI/Exeltis, USA, Frictionless Solutions, Schipher, Crealta/Horizon, Medisys, Fidia, PK Med, Two Labs, Adept Field Solutions, Clinical Care Options, Putnam Associates, Focus Forward, Navigant Consulting, Spherix, MedIQ, Jupiter Life Science, UBM LLC, Trio Health, Medscape, WebMD, Practice Point Communications, the National Institutes of Health, and the American College of Rheumatology; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from the speaker’s bureau of Simply Speaking; support for attending meetings and travel as a past steering committee member of OMERACT, an international organization that develops measures for clinical trials and receives arm’s length funding from 12 pharmaceutical companies; participation on a Data Safety Monitoring Board or Advisory Board, unpaid, with FDA Arthritis Advisory Committee; leadership or fiduciary roles in board, society, committee or advocacy groups, paid or unpaid with leadership or fiduciary roles in board, society, committee or advocacy groups, paid or unpaid with OMERACT as past steering committee member; stock or stock options in Atyr Pharmaceuticals, Atai Life Sciences, Kintara Therapeutics, Intelligent Biosolutions, Acumen Pharmaceutical, TPT Global Tech, Vaxart Pharmaceuticals, Atyu Biopharma, Adaptimmune Therapeutics, GeoVax Labs, Pieris Pharmaceuticals, Enzolytics, Seres Therapeutics, Tonix Pharmaceuticals Holding, Aebona Pharmaceuticals, and Charlotte’s Web Holdings; and previously owned stock options in Amarin, Viking, and Moderna Pharmaceuticals; all outside the submitted work. Sa Singh reports support for the present manuscript from the Indian Council of Medical Research (project ID: 2021-6329). R Tabares-Seisdedos reports grants or contracts from Valencian Regional Government’s Ministry of Education (PROMETEO/ CIPROM/2022/58) and the Spanish Ministry of Science, Innovation and Universities (PID2021-129099OB-I00) outside the submitted work; the funders were not involved in the design of the manuscript or decision to submit the manuscript for publication, nor will they be involved in any aspect of the study’s conduct. J H V Ticoalu reports leadership or fiduciary roles in board, society, committee or advocacy groups, paid or unpaid with Benang Merah Research Center (benangmerah.net) as co-founder outside the submitted work. M Zielińska reports other financial or non-financial interests as an Alexion, AstraZeneca Rare Disease employee, outside the submitted work.